FCGR3A and lymphoma: In preclinical models, FcγR‐mediated cytotoxicity contributes substantially to the efficacy of depleting antibodies such as the anti‐HER2 antibody trastuzumab, rituximab, and alemtuzumab,3, 4 and higher affinity allotypic forms of the human activating FcγRIIIA as well as genotypic variants of the activating FcγRIIA were shown to be associated with improved clinical outcomes in rituximab‐treated lymphoma patients in some 5, 6, 7 but not all 8 studies.